专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20040137614A1 Human ovarian mesothelial cells and methods of isolation and uses thereof 失效
标题翻译：人卵巢间皮细胞及其分离方法及用途
公开(公告)号：US20040137614A1
公开(公告)日：2004-07-15
申请号：US10744508
申请日：2003-12-22
发明人： Rong-Hao Li , Laura Bald , Jennie Powell Mather
IPC分类号： G01N033/574 , C12N005/08
CPC分类号： C12N5/0682 , A61K35/12 , C12N5/0697 , C12N2500/25 , C12N2500/36 , C12N2501/11 , C12N2501/195 , C12N2501/70 , C12N2502/243 , C12N2502/25 , C12N2503/02 , G01N33/5011 , G01N33/57449 , G01N2333/4742
摘要： The invention discloses a substantially pure population of human ovarian mesothelial cells and methods of isolating and culturing the ovarian mesothelial cells. By carefully manipulating the microenvironment of the ovarian mesothelial cells, multiple passages are attainable wherein the ovarian mesothelial cells are capable of becoming ovary surface epithelial cells or granulosa cells. In addition, several methods of use of human ovarian mesothelial cells are disclosed herein.
摘要翻译：本发明公开了一种基本纯净的人类卵巢间皮细胞群，以及分离和培养卵巢间皮细胞的方法。通过仔细操纵卵巢间皮细胞的微环境，可以进行多次传代，其中卵巢间皮细胞能够成为卵巢表面上皮细胞或颗粒细胞。此外，本文公开了使用人卵巢间皮细胞的几种方法。

42. 发明申请

US20040137455A1 Diagnosis of cancer or benign tumor using the aberrant expression product of the klk4 gene 审中-公开
标题翻译：使用klk4基因的异常表达产物诊断癌症或良性肿瘤
公开(公告)号：US20040137455A1
公开(公告)日：2004-07-15
申请号：US10473485
申请日：2004-03-15
发明人： Ying Dong , Judith Ann Clements
IPC分类号： C12Q001/68 , G01N033/574
CPC分类号： C12N9/6445 , A61K38/1709 , C07K16/40 , G01N33/57434 , G01N33/57442 , G01N33/57449 , G01N33/57496
摘要： The present invention discloses aberrant expression products of the KLK4 gene, which segregate with at least one condition selected from a cancer or a benign tumour. The invention also discloses a method for detecting the presence or diagnosing the risk of said at least one condition by detecting aberrant KLK4 expression The invention also discloses isolated polynucleotides comprising a nucleotide sequence that corresponds or is complementary to at least a portion of an aberrant KLK4 polynucleotide, which correlates with the presence or risk of said at least one condition. Also disclosed are isolated polypeptides comprising an amino acid sequence that corresponds to at least a portion of an aberrant K4 polypeptide, which correlates with the presence or risk of said at least one condition. The invention also extends to variants and derivatives of these molecules, to vectors comprising aberrant KLK4 polynucleotides and to host cells containing such vectors. The invention further extends to antigen-binding molecules that are immuno-interactive with aberrant K4 polypeptides and to the use of these antigen-binding molecules, the aberrant KLK4 polynucleotides and aberrant K4 polypeptides in assays and kits for detecting the presence or diagnosing the risk of said at least one condition. The invention further encompasses the use of functional KLK4 polynucleotides or functional K4 polypeptides or agents that modulate the level and/or functional activity of an expression product of KLK4 or of a gene belonging to the same biosynthetic or regulatory pathway as KLK4 for treating and/or preventing one or more of said conditions.
摘要翻译：本发明公开了KLK4基因的异常表达产物，其与至少一种选自癌症或良性肿瘤的病症分离。本发明还公开了通过检测异常KLK4表达来检测存在或诊断所述至少一种病症的风险的方法。本发明还公开了分离的多核苷酸，其包含与异常KLK4多核苷酸的至少一部分相对应或互补的核苷酸序列，其与所述至少一个条件的存在或风险相关。还公开了分离的多肽，其包含对应于异常K4多肽的至少一部分的氨基酸序列，其与所述至少一种病症的存在或风险相关。本发明还延伸到这些分子的变体和衍生物，包含异常KLK4多核苷酸的载体和含有这些载体的宿主细胞。本发明进一步扩展到与异常K4多肽免疫相互作用的抗原结合分子以及这些抗原结合分子，异常KLK4多核苷酸和异常K4多肽在测定和试剂盒中的用途，用于检测其存在或诊断风险说至少有一个条件。本发明还包括使用功能性KLK4多核苷酸或功能性K4多肽或调节KLK4或属于与KLK4相同的生物合成或调节途径的基因的表达产物的水平和/或功能活性的药剂，用于治疗和/或防止一种或多种所述条件。

43. 发明申请

US20040131623A9 Tumor homing molecules, conjugates derived therefrom, and methods of using same 审中-公开
标题翻译：肿瘤归巢分子，衍生自其的共轭物及其使用方法
公开(公告)号：US20040131623A9
公开(公告)日：2004-07-08
申请号：US10375992
申请日：2003-02-27
申请人： THE BURNHAM INSTITUTE
发明人： Erkki Ruoslahti , Renata Pasqualini
IPC分类号： G01N033/574 , A61K039/395
CPC分类号： G01N33/5011 , A61K47/64 , G01N33/57492 , G01N2333/70546 , G01N2333/948
摘要： The present invention provides tumor homing molecules, which selectively home to a tumor. The invention also provides methods of using a tumor homing molecule to target an agent such as a drug to a selected tumor or to identify the target molecule expressed by the tumor. The invention also provides methods of targeting a tumor containing angiogenic vasculature by contacting the tumor with a molecule that specifically binds an nullv-containing integrin. The invention further provides molecules that can selectively home to angiogenic vasculature. In addition, the invention provides a target molecule, which is specifically bound by a tumor homing molecule and is expressed by angiogenic vasculature. The invention also provides antibodies that bind to the target molecule and peptidomimetics that competitively inhibit binding of a ligand to the target molecule.
摘要翻译：本发明提供了肿瘤归巢分子，其选择性地归巢于肿瘤。本发明还提供使用肿瘤归巢分子将药物如药物靶向所选择的肿瘤或鉴定由肿瘤表达的靶分子的方法。本发明还提供了通过使肿瘤与特异性结合含alphav的整联蛋白的分子接触来靶向含有血管生成脉管系统的肿瘤的方法。本发明进一步提供可以选择性地归属于血管生成脉管系统的分子。此外，本发明提供了靶分子，其特异性地被肿瘤归巢分子结合并且由血管生成脉管系统表达。本发明还提供了结合靶分子的抗体和竞争性抑制配体与靶分子结合的肽模拟物。

44. 发明申请

US20040121414A1 Method for diagnosis of hepatocellular carcinoma using TGFBETA 1 as a serologic marker 审中-公开
标题翻译：使用TGFBETA 1作为血清学标记物诊断肝细胞癌的方法
公开(公告)号：US20040121414A1
公开(公告)日：2004-06-24
申请号：US10329255
申请日：2002-12-23
发明人： Young-Hwa Chung , Byung-Cheol Song , Jeong A. Kim
IPC分类号： G01N033/574
CPC分类号： G01N33/57438 , G01N33/57488 , G01N2333/495
摘要： The present invention relates to a method for diagnosis of hepatocellular carcinoma using TGF-null 1 as a serologic marker, particularly, to a method for diagnosis of hepatocellular carcinoma in which hepatocellular carcinoma can be identified by measuring the level of TGF-null 1 in plasma or serum. Since TGF-null 1 is highly sensitive as a serologic marker comparing to AFP that has been widely used as a serologic marker for the detection of hapatoma, TGF-null 1, as a serologic marker, is very useful for the accurate early detection and diagnosis of hepatocellular carcinoma.
摘要翻译：本发明涉及使用TGF-β1作为血清标志物的肝细胞癌的诊断方法，特别涉及通过测量血浆中TGF-β1的水平可以鉴定肝细胞癌的肝细胞癌的诊断方法或血清。由于与被广泛用作血清学标记物用于检测反义瘤的AFP相比，TGF-β1作为血清学标记高度敏感，所以作为血清学标记的TGF-β1对于准确的早期检测和诊断是非常有用的的肝细胞癌。

45. 发明申请

US20040116658A1 Human KAP/Cdi1-related gene variant associated with small cell lung cancer 审中-公开
标题翻译：人类KAP / Cdi1相关基因变异与小细胞肺癌相关
公开(公告)号：US20040116658A1
公开(公告)日：2004-06-17
申请号：US10103957
申请日：2002-03-22
发明人： Ken-Shwo Dai
IPC分类号： C12Q001/68 , G01N033/574 , C07H021/04 , C07K014/74 , C07K016/30 , C12P021/02 , C12N005/06
CPC分类号： C12N9/16 , C12Q1/6886 , C12Q2600/156
摘要： The invention relates to the nucleic acid and polypeptide sequences of a novel human KAP/Cdi1-related gene variant (KAP1). The invention also relates to the process for producing the polypeptide of the variant. The invention further relates to the use of the nucleic acid and polypeptide of the gene variant in diagnosing diseases, in particular, lung cancer, e.g. small cell lung cancer.
摘要翻译：本发明涉及新的人KAP / Cdi1相关基因变体（KAP1）的核酸和多肽序列。本发明还涉及生产该变体多肽的方法。本发明还涉及基因变体的核酸和多肽在诊断疾病，特别是肺癌中的用途，例如，小细胞肺癌。

46. 发明申请

US20040115747A1 Screening assays for compounds that cause apoptosis 失效
标题翻译：导致凋亡的化合物的筛选试验
公开(公告)号：US20040115747A1
公开(公告)日：2004-06-17
申请号：US10633789
申请日：2003-08-04
申请人： The Gov. of the USA as represented by the Secretary of the Dep. of Health and Human Services
发明人： Curtis C. Harris , Xin Wei Wang , Jan H.J. Hoeijmakers
IPC分类号： G01N033/574
CPC分类号： A61K38/1709 , C07K14/4746 , C07K2319/00
摘要： This invention relates to methods of screening for compounds capable of inducing apoptosis in certain tumor cells. The invention also relates to compounds identified by such methods. In addition, the invention relates to methods for the in vitro diagnosis of Xeroderma pigmentosum and compounds useful in these methods.
摘要翻译：本发明涉及筛选能够诱导某些肿瘤细胞凋亡的化合物的方法。本发明还涉及通过这些方法鉴定的化合物。此外，本发明涉及用于这些方法中有用的皮肤色素调色剂和化合物的体外诊断方法。

47. 发明申请

US20040115708A1 Method of screening agents for the treatment and prevention of cancer and cachexia and the new use of specific agents for the treatment and prevention of cancer and cachexia 审中-公开
标题翻译：用于治疗和预防癌症和恶病质的筛选剂的方法以及用于治疗和预防癌症和恶病质的特定药剂的新用途
公开(公告)号：US20040115708A1
公开(公告)日：2004-06-17
申请号：US10665221
申请日：2003-09-17
发明人： C. Murray Ardies
IPC分类号： C12Q001/68 , G01N033/574
CPC分类号： C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , G01N33/5011
摘要： A method for screening agents to determine possible use as treatment and prevention drugs is provided. More specifically, cells, living organisms, mammals, or tissue are treated with the compound or agent of interest and then measured for transient activation of stress-response pathways. Activation of any of the genes or signaling molecules associated with a stress-response pathway is then determined. A transient activation of any of the genes within these pathways of transcription activation indicates the agent is a candidate for a drug, or a source of a drug for the treatment and prevention of cachexia, other wasting disorders, cancer, atherosclerosis, heart disease, autoimmune disease, chronic inflammatory disease, alcoholic hepatitis, non-alcoholic hepatitis, rheumatoid arthritis, osteoarthritis, type II diabetes, insulin insensitivity, Parkinson's disease, Alzheimer's disease, and any other condition caused or mediated by chronic oxygen radical damage or by chronic chemical toxicities. Methods of treatment and uses of specific agents are also provided.
摘要翻译：提供了筛选试剂以确定作为治疗和预防药物的可能用途的方法。更具体地，用感兴趣的化合物或药剂处理细胞，活生物体，哺乳动物或组织，然后测量应激反应途径的瞬时活化。然后确定与应激反应途径相关联的任何基因或信号分子的活化。这些转录激活途径中任何基因的瞬时激活表明该药物是药物的候选物，或用于治疗和预防恶病质，其它消耗疾病，癌症，动脉粥样硬化，心脏病，自身免疫的药物的来源疾病，慢性炎性疾病，酒精性肝炎，非酒精性肝炎，类风湿性关节炎，骨关节炎，II型糖尿病，胰岛素不敏感，帕金森病，阿尔茨海默病以及由慢性氧自由基损伤或慢性化学毒性引起或介导的任何其他病症。还提供了治疗和使用特定药剂的方法。

48. 发明申请

US20040110221A1 Methods for diagnosing RCC and other solid tumors 失效
标题翻译：诊断RCC和其他实体瘤的方法
公开(公告)号：US20040110221A1
公开(公告)日：2004-06-10
申请号：US10717597
申请日：2003-11-21
申请人： Wyeth
发明人： Natalie C. Twine , Michael E. Burczynski , William L. Trepicchio , Andrew J. Dorner , Jennifer A. Stover , Donna K. Slonim
IPC分类号： C12Q001/68 , G01N033/574
CPC分类号： G01N33/57438 , C12Q1/6837 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G06F19/20
摘要： Methods, systems and equipment for diagnosing renal cell carcinoma (RCC) and other solid tumors. This invention identifies numerous disease genes that are differentially expressed in the peripheral blood of patients having RCC or other solid tumors relative to disease-free humans. These disease genes can be used as surrogate markers for detecting the presence or absence of RCC or other solid tumors.
摘要翻译：用于诊断肾细胞癌（RCC）和其他实体瘤的方法，系统和设备。本发明鉴定了相对于无病人的患有RCC或其他实体瘤的患者的外周血中差异表达的许多疾病基因。这些疾病基因可用作检测RCC或其他实体瘤存在或不存在的替代标记。

49. 发明申请

US20040106161A1 Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies 审中-公开
标题翻译：用于鉴定对抗ErbB2抗体治疗有反应的肿瘤的方法
公开(公告)号：US20040106161A1
公开(公告)日：2004-06-03
申请号：US10619754
申请日：2003-07-14
发明人： Birgit Bossenmaier , Hans-Joachim Muller , Hans Koll , Mark X. Sliwkowski , Stephen Michael Kelsey
IPC分类号： G01N033/574 , C07K016/30
CPC分类号： C07K16/32 , A61K2039/505 , C07K2317/24 , G01N33/57492 , G01N2333/485 , G01N2333/71 , G01N2800/52
摘要： Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.
摘要翻译：通过检测HER2 / HER3和/或HER2 / HER1蛋白复合物的存在或肿瘤细胞样品中的HER2磷酸化，确定肿瘤对抗HER2抗体的治疗有反应。患有包含HER / 2 / HER1和/或HER2 / HER3异源二聚体和/或HER2磷酸化的肿瘤的患者用抗HER2抗体如rhuMAb 2C4处理。

50. 发明申请

US20040106143A1 Monoclonal antibody against estrogen stimulated leucine aminopeptidase 审中-公开
标题翻译：针对雌激素刺激的亮氨酸氨基肽酶的单克隆抗体
公开(公告)号：US20040106143A1
公开(公告)日：2004-06-03
申请号：US10705991
申请日：2003-11-12
发明人： Gabriel Pulido-Cejudo
IPC分类号： C12Q001/68 , G01N033/574
CPC分类号： G01N33/56988 , A61K38/4813 , A61K39/395 , A61K2039/505 , C07K16/3015 , C07K16/40 , C12Q1/37 , G01N33/573 , G01N33/57415 , Y10S435/975 , A61K2300/00
摘要： The identification and characterization of risk factors and their molecular implications in the pathophysiology of human diseases such as cancer is essential for designing efficient diagnostic assays and therapeutic compounds. Estrogenic steroids, under normal physiological conditions, have been shown to play a critical function in several tissues. The response of such a variety of tissues to estrogen stimulation can explain in part its active role in the development and progression of different human diseases, particularly Breast Cancer. Searching for estrogen-responding cellular factors in parental cells of primary human breast carcinomas obtained from tumour biopsies an isoenzyme of putative Leucine Aminopeptidase (LAPase; EC 3.4.11.1) was identified. Results have demonstrated that this marker is found to be elevated in the sera of women with invasive ductal and metastatic carcinomas. A monoclonal antibody against this cellular marker have been produced. This invention refers to the use of LAPase monoclonal antibodies for first line confirmatory blood-based testing for Breast Cancer.
摘要翻译：识别和表征危险因素及其在人类疾病如癌症的病理生理学中的分子意义对于设计有效的诊断测定和治疗化合物至关重要。在正常生理条件下，雌激素类固醇已显示在几种组织中起关键作用。这种多种组织对雌激素刺激的反应可以部分解释其在不同人类疾病，特别是乳腺癌的发展和进展中的积极作用。在从肿瘤活检中获得的原代人乳腺癌的亲代细胞中寻找雌激素反应性细胞因子，鉴定出推定的亮氨酸氨基肽酶（LAPase; EC 3.4.11.1）的同工酶。结果表明，这种标志物被发现在具有浸润性导管和转移性癌症的妇女的血清中升高。已经产生了针对该细胞标记物的单克隆抗体。本发明涉及使用LAPase单克隆抗体进行乳腺癌一线验证性血液检测。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式